Stock Groups

Purdue Pharma can appeal rejection of bankruptcy plan -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILEPHOTO: On May 9, 2019, a pharmacist in Provo holds a Purdue Pharma OxyContin. REUTERS/George Frey

NEW YORK (Reuters), Purdue Pharma allowed Friday’s U.S. court decision to allow Purdue Pharma to contest her refusal of legal protections to the Sackler family who are OxyContin makers. This was critical to Purdue Pharma’s bankruptcy reorganization plan.

Purdue is now able to appeal the decision of U.S. District Court Judge Colleen McMahon that allows it to keep intact the $4.5 billion settlement in opioid litigation. This was the core of its plan.

McMahon had reversed a bankruptcy judge’s order approving the deal in December. So-called “nondebtor” releases are provided to shield the Sacklers in future opioid-related lawsuits.

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media does not accept any liability for trade losses you may incur due to the use of these data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of the potential risks and financial costs involved in trading the financial market. It is among the most risky forms of investment.

[ad_2]